The success of Sildenafil initially sparked a period of growth for pharma, but recent changes present a murky scenario for shareholders. Off-patent versions are eating into earnings, and persistent patent challenges https://diegozbox293779.qowap.com/100221180/sildenafil-and-the-pharmaceutical-industry-a-precarious-investment